Latest Ipilimumab Stories
Melanoma patients lived longer with treatment SILVER SPRING, Md., March 25, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer.
Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone.
HACKENSACK, N.J., Sept.
A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma.
Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas.
Researchers have made significant advances in the treatment of metastatic malignant melanoma â€“ one of the most difficult cancers to treat successfully once it has started to spread â€“ according to a study to be presented at Europe's largest cancer congress, ECCO 15 â€“ ESMO 34 , in Berlin on Thursday.
Patients with stage III or IV melanoma taking ipilimumab and the oral steroid budesonide to reduce side effects did not have less diarrhea, a known side effect of ipilimumab, according to results of a phase II trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
SAN FRANCISCO, Aug. 3 /PRNewswire/ -- Biotech was "hot" in July driven by drug data, positive drug sales/earnings and partnering and M&A deals.
- Large; stout; burly.